KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesR&D In ProcessReceivables - NetReceivables - OtherShares Repurchased
Ratios

Eli Lilly (LLY) Receivables - Other (2016 - 2025)

Eli Lilly (LLY) has disclosed Receivables - Other for 14 consecutive years, with $2.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Other rose 5.51% year-over-year to $2.4 billion, compared with a TTM value of $2.4 billion through Dec 2025, up 5.51%, and an annual FY2025 reading of $2.4 billion, up 5.51% over the prior year.
  • Receivables - Other was $2.4 billion for Q4 2025 at Eli Lilly, down from $3.3 billion in the prior quarter.
  • Across five years, Receivables - Other topped out at $3.3 billion in Q3 2025 and bottomed at $1.1 billion in Q1 2021.
  • Average Receivables - Other over 5 years is $1.9 billion, with a median of $1.7 billion recorded in 2022.
  • The sharpest move saw Receivables - Other dropped 20.02% in 2024, then surged 90.67% in 2025.
  • Year by year, Receivables - Other stood at $1.5 billion in 2021, then rose by 14.34% to $1.7 billion in 2022, then surged by 35.05% to $2.2 billion in 2023, then increased by 1.08% to $2.3 billion in 2024, then rose by 5.51% to $2.4 billion in 2025.
  • Business Quant data shows Receivables - Other for LLY at $2.4 billion in Q4 2025, $3.3 billion in Q3 2025, and $3.0 billion in Q2 2025.